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Abstract
Background
The efficacy and safety of warfarin therapy for stroke prevention in atrial fibrillation (AF)
depends on the time in therapeutic range (TTR). We aimed to assess the predictive ability
of SAMe-TT2R2 score in Chinese AF patients on warfarin, whose TTR is notoriously poor.
Methods and Results
This is a single-centre retrospective study. Patients with non-valvular AF on warfarin diag-
nosed between 1997 and 2011 were stratified according to SAMe-TT2R2 score, and TTR
was calculated using Rosendaal method. The predictive power of SAMe-TT2R2 scores for
good TTR i.e. >70% was assessed. We included 1,428 Chinese patients (mean age 76.2
±8.7 years, 47.5% male) with non-valvular AF on warfarin. The mean and median TTR were
38.2±24.4% and 38.8% (interquartile range: 17.9% and 56.2%) respectively. TTR
decreased progressively with increasing SAMe-TT2R2 score (p = 0.016). When the cut-off
value of SAMe-TT2R2 score was set to 2, the sensitivity and specificity to predict TTR<70%
were 85.7% and 17.8%, respectively. The corresponding positive and negative predictive
values were 10.1% and 92.0%. After a mean follow-up of 4.7±3.6 years, 338 patients devel-
oped an ischemic stroke (4.96%/year). Patients with TTR70% had a lower annual risk of
ischemic stroke of 3.67%/year compared with than those with TTR<70% (5.13%/year)(p =
0.08). Patients with SAMe-TT2R2 score2 had the lowest risk of annual risk of ischemic
stroke (3.49%/year) compared with those with SAMe-TT2R2 score = 3 (4.56%/year), and
those with SAMe-TT2R2 score4 (6.41%/year)(p<0.001). There was also a non-significant
trend towards more intracranial hemorrhage with increasing SAMe-TT2R2 score.
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Conclusions
The SAMe-TT2R2 score correlates well with TTR in Chinese AF patients, with a score >2
having high sensitivity and negative predictive values for poor TTR. Ischemic stroke risk
increased progressively with increasing SAMe-TT2R2 score, consistent with poorer TTRs at
high SAMe-TT2R2 scores.
Introduction
Warfarin therapy effectively reduces ischemic stroke and mortality amongst patients with non-
valvular atrial fibrillation (AF).[1–3] The efficacy and safety of warfarin, however, very much
depends on the quality of anticoagulation control, as assessed by the time in therapeutic range
(TTR), with the proportion of time spent within therapeutic range of 2.0–3.0.[4–7] It is gener-
ally accepted that patients on warfarin should spend more than 65%, or even 70%, of time with
INR between 2–3 to obtain the benefit as well as safety of the therapy.[8, 9] In Asian countries,
anticoagulation control is notoriously poor, both in real world practice and in randomized clin-
ical trials.[10]
Recently, a new clinical score, the SAMe-TT2R2 score was derived and validated using a pri-
marily white Caucasian population to predict the likelihood of AF patients on warfarin of hav-
ing a good TTR (with SAMe-TT2R2 score 0–2).[11] Given that non-Caucasian race already
confers 2 points in this score, the SAMe-TT2R2 score requires validation and/or re-calibration
in a non-Caucasian population.
In this study, we aimed, for the first time, to evaluate the ability of SAMe-TT2R2 score in
predicting the quality of anticoagulation control (as reflected by TTR) in an Asian population.
Methods
Study Design and Patients
This was a retrospective study based on a hospital-based AF registry as previously described,
[2–4, 12, 13] and was approved by the Institutional Review Board of the University of Hong
Kong / Hospital Authority Hong Kong West Cluster. Consent was waived as all the data were
analyzed anonymously. Briefly, patients18 years of age diagnosed to have AF in Queen Mary
Hospital, Hong Kong, from July 1997 to December 2011, were identified via a computerized
database of clinical management system. Patients were excluded from the current study if they
had significant valvular heart disease (i.e. prosthetic heart valve, rheumatic heart disease), less
than 10 retrievable INR measurements, or interruption of warfarin for>2 weeks. Those with
incomplete data or missing follow up were excluded from this study.
Definitions
The SAMe-TT2R2 score (S: Sex [female] [1 point]; A: age<60 years [1 point];Me: Medical
History [>2 of the following comorbidities: hypertension, diabetes, coronary artery disease/
myocardial infarction, peripheral arterial disease, congestive heart failure, previous stroke, pul-
monary disease, hepatic or renal disease] [1 [point]; T: Treatment [interacting drugs e.g. Amio-
darone for rhythm control] [1 point]; T: Tobacco use (within 2 years) [2 points]; and R: Race
[non-white] [2 points] was calculated for each individual.[11] Since all patients in our study
were Chinese i.e. non-White population, the minimum score will be 2 points. Subsequent
SAMe-TT2R2 for Chinese
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occurrence of risk factor contributory to the SAMe-TT2R2 score had not been taken into
account.
In addition, ischemic stroke risk was estimated at baseline using the CHA2DS2-VASc score
(C: congestive heart failure [1 point];H: hypertension [1 point]; A2: age 65–74 years [1 point]
and age75 years [2 points];D: diabetes mellitus [1 point]; S: prior stroke or transient ische-
mic attack [2 points]; VA: vascular disease [1 point]; and Sc: sex category [female] [1 point]) as
described in recent guidelines.[14] Likewise, the HAS-BLED score was calculated at baseline as
a measure of bleeding risk.[15] Uncontrolled hypertension was defined as systolic blood pres-
sure>160 mmHg at baseline and subsequent visit-to-visit changes in systolic blood pressure
had not been taken in account. Similarly, liver disease as determined by the derangement in
liver biochemistry and renal disease as determined by serum creatinine level were only assessed
at baseline, subsequent changes had not been taken into account.
According to the center’s protocol, INR was measured every 8 weeks and more frequently
when INR was not within the therapeutic range. The TTR was calculated for each patient using
Rosendaal method, [16] in which INR was assumed to change in a linear manner between mea-
surements, and INR values on the days with no measurement were interpolated. However, INR
measurements within the first 6 weeks of warfarin therapy were excluded from this analysis
due to the more frequent INR testing and large fluctuation in measurements during initial war-
farin adjustment. The percentage of time during which a patient had an INR within 2.0–3.0
was taken as the TTR. According to the European guidelines, [9] a TTR70% was considered
the criterion for ‘good anticoagulation control’.[8]
Statistical Analysis
Continuous and discrete variables are expressed as mean ± standard derivation and percent-
ages, respectively. Statistical comparisons of the baseline clinical characteristics were performed
using Student’s t test, Mann-Whitney U test, or one-way ANOVA as appropriate. Binary and
linear hazards regression models were used to calculate hazard ratios (HRs) of some predictive
factors and their 95% confidence interval (CIs) for poor anticoagulation control, TTR<70%.
The predictive performance of the SAMe-TT2R2 score for ischemic stroke was assessed using
the c-statistics (area under the curve). The c-statistic for receiver operating characteristic curve
was calculated using Analyze-It for Excel with the Delong-Delong comparison for c-statistic.
The c-statistic integrates measures of sensitivity and specificity of the range of a variable. Ideal
prediction yields a c-statistic of 1.00 whereas a value of<0.5 indicates that the prediction is no
better than chance. Calculations were performed using SPSS software (version 21.0) and Med-
Cal (version 13.1.2). All tests were two-sided, and p-values were considered significant if
<0.05.
Results
We included 1,428 Chinese patients (mean age 76.2±8.7 years, 47.5% male) with non-valvular
AF on warfarin [Table 1]. The mean and median TTR overall were 38.2±24.4% and 38.8%
(interquartile range: 17.9% and 56.2%) respectively. During the 14-year study period, the mean
INR improved from 37.3±23.7% between 1997 and 2001 and 36.8±24.1% between 2002 and
2007, to 43.1±26.0% between 2008 and 2011. As in the original derivation cohort and subse-
quent external validation cohort, TTR decreased progressively with increasing SAMe-TT2R2
score (p = 0.016) (Fig 1). Even amongst patients with the lowest SAMe-TT2R2 score, i.e., 2,
TTR was only 41.0±23.3%, which decreased to 39.0±25.0% and 36.0±24.0% amongst patients
with SAMe-TT2R2 score of 3, and4 respectively.
SAMe-TT2R2 for Chinese
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In the whole cohort, only 154 patients (10.7%) had good anticoagulation control (i.e.,
TTR70%) and were younger (73.8±9.2 years vs. 76.4±8.6 years, p<0.01), had a higher pro-
portion with age<60 years (7.1% vs. 2.9%, p<0.01), and previous stroke/transient ischemic
stroke (44.2% vs. 33.6%, p<0.01), compared with those with TTR<70%. Table 2 summarizes
the HRs and the corresponding 95% CIs of baseline characteristics to poor TTR (TTR<70%)
in both univariate and multivariate analysis. Of note, diabetes mellitus and heart failure were
independently associated with TTR<70%, whereas age less than 60 years, previous stroke or
transient ischemic attack, and lower SAMe-TT2R2 score appeared to be associated with good
TTR (Table 2).
When the cutoff value of SAMe-TT2R2 score was set to 2, the sensitivity and specificity to
predict TTR70% were 85.7% and 18.2%, respectively. The corresponding positive and nega-
tive predictive values were 11.2% and 91.3%. The Youden index was 0.039. If the cutoff value to
predict TTR70% was set to 3, the sensitivity and specificity to detect TTR70% were lower,
being 66.2% and 37.4%, respectively; however, the positive and negative predictive values were
similar, being 11.8% and 89.7%, respectively. The Youden index for the cutoff of 3 was 0.036.
After a mean follow-up of 4.7±3.6 years, 338 patients developed an ischemic stroke with an
annual incidence of 4.96%/year. Patients with TTR70% had a lower annual risk of ischemic
Table 1. Baseline characteristics.
All (n = 1,428) TTR p-value1
70% (n = 154) <70% (n = 1,274)
Mean age, (yrs) 76.2±8.7 73.8±9.2 76.4±8.6 <0.01*
Age<60 years, n (%) 48 (3.4) 11 (7.1) 37 (2.9) <0.01*
Female, n (%) 671 (52.5) 79 (51.3) 671 (52.7) 0.75
HT, n (%) 922 (64.6) 102 (66.2) 820 (64.4) 0.65
DM, n (%) 387 (27.1) 32 (20.8) 355 (27.9) 0.06
Tobacco use (within 2 yrs), n (%) 71 (5.0) 11 (7.1) 60 (4.7) 0.19
Dialysis, n (%) 29 (2.0) 0 (0) 29 (2.3) 0.07
Heart failure, n (%) 367 (25.7) 335 (26.3) 32 (20.8) 0.14
CAD, n (%) 407 (28.5) 365 (28.6) 42 (27.3) 0.72
PAD, n (%) 102 (7.1) 13 (8.4) 89 (7.0) 0.51
Stroke/TIA, n (%) 496 (34.7) 68 (44.2) 428 (33.6) <0.01*
CHA2DS2-VASc
Mean CHA2DS2-VASc 4.2±1.6 4.1±1.5 4.2±1.6 0.34
Median CHA2DS2-VASc (IQR) 4 (3, 5) 4 (3, 5) 4 (3, 5) 0.42
Mean HAS-BLED 2.3±0.9 2.3±0.9 2.3±0.9 0.83
Treatment with interacting drugs 94 (6.6) 10 (6.5) 84 (6.6) 0.96
SAMe-TT2R2 score 0.02*
2, n (%) 254 (17.8) 22 (14.3) 232 (18.2)
3, n (%) 646 (45.2) 80 (51.9) 566 (44.4)
4, n (%) 442 (31.0) 41 (26.6) 401 (31.5)
5, n (%) 75 (5.3) 7 (4.5) 68 (5.3)
6, n (%) 11 (0.8) 4 (2.6) 7 (0.5)
Abbreviations: CAD: Coronary artery disease; DM: diabetes mellitus; IQR: interquartile range; PAD: peripheral arterial disease; TIA: transient ischemic
attack.
1p-value for comparison between patients with TTR 70% and TTR<70%.
* p-value <0.05
doi:10.1371/journal.pone.0150674.t001
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Fig 1. Relation between different SAMe-TT2R2 scores and the time of therapeutic range (TTR) in
Chinese AF patients.
doi:10.1371/journal.pone.0150674.g001
Table 2. Association between baseline factors and poor time in therapeutic range (TTR) <70%).
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age<60 years 0.39 (0.19–0.80) 0.008* 0.39 (0.18–0.84) 0.016*
Female 1.06 (0.76–1.48) 0.75
HT 0.92 (0.64–1.31) 0.65
DM 1.47 (0.98–2.21) 0.06 1.57 (1.02–2.41) 0.04*
Tobacco use within 2 yrs 0.64 (0.33–1.25) 0.19
Heart failure 1.36 (0.90–2.05) 0.14 1.33 (0.87–2.04) 0.19
CAD 1.07 (0.74–1.56) 0.72
PAD 0.82 (0.44–1.50) 0.51
Stroke/TIA 0.64 (0.46–0.90) 0.01* 0.64 (0.45–0.90) 0.01*
CHA2DS2-VASc 1.05 (0.95–1.17) 0.34
HAS-BLED 1.02 (0.84–1.24) 0.83
Treatment with interacting drugs 1.02 (0.52–2.00) 0.96
SAMe-TT2R2 score 0.037* 0.15
2, n (%) Reference Reference
3, n (%) 0.67 (0.41–1.10) 0.12 0.58 (0.35–0.96) 0.04*
4, n (%) 0.93 (0.54–1.60) 0.79 0.77 (0.43–1.38) 0.39
 5, n (%) 0.65 (0.30–1.40) 0.27 0.67 (0.28–1.60) 0.47
* p-value <0.05
doi:10.1371/journal.pone.0150674.t002
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stroke of 3.67%/year compared with than those with TTR<70% 5.13%/year (p = 0.08). The
SAMe-TT2R2 score showed a significant association with annual risk of ischemic stroke. Fig 2
shows a Kaplan Meier analysis of ischemic stroke amongst patients with different strata of
SAMe-TT2R2 score (Log-rank: 16.0, P<0.001). Patients with SAMe-TT2R2 score2 had the
lowest risk of annual risk of ischemic stroke (3.49%/year) compared with those with SAMe-
TT2R2 score = 3 (4.56%/year), and those with SAMe-TT2R2 score4 (6.41%/year)(p<0.001).
Fig 3 summarizes HR and the corresponding 95% CIs of different strata of SAMe-TT2R2 score
for ischemic stroke. At follow up, there were altogether 63 intracranial haemorrhages with
annual incidence of 0.90%/year. There was a non-significant trend towards more events with
increasing SAMe-TT2R2 score, with events rates at scores 2, 3 and4 being 0.77%/year,
0.96%/year (HR: 1.23, 95% CI: 0.62–2.45), and 0.90%/year (HR: 1.09, 95% CI: 0.52–2.26),
respectively. However, the area under the curve of the SAMe-TT2R2 score for stroke prediction
was only 0.543 (95% CI: 0.52–0.57) with the Youden index of 0.08.
Fig 2. Kaplan-Meier estimates of ischemic stroke-free survival in Chinese AF patients with different
SAMe-TT2R2 scores.
doi:10.1371/journal.pone.0150674.g002
Fig 3. Hazard Ratios of different strata of SAMe-TT2R2 scores on ischemic stroke.Horizontal lines
represent 95% confident intervals (CIs) around point estimates.
doi:10.1371/journal.pone.0150674.g003
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Discussion
In this study, we have shown for the first time that amongst Chinese AF patients on warfarin,
the SAMe-TT2R2 correlated with TTR in Chinese AF patients, with a SAMe-TT2R2 score>2
having a high sensitivity and negative predictive value for good TTR. Second, recalibration of
the score in this non-Caucasian population did not improve its sensitivity. Third, the incidence
of ischemic stroke increased progressively with increasing SAMe-TT2R2 score, consistent with
poor TTRs at high SAMe-TT2R2 scores.
The importance of good quality anticoagulation control amongst patients on warfarin ther-
apy typically with a TTR above 65% to 70% cannot be emphasized. In Asian population includ-
ing Chinese, quality of anticoagulation has generally been poor [10], with a median TTR
amongst Chinese AF patients being as low as 38.8% in the present cohort. Poor TTR under-
mines not only the efficacy of the therapy (more ischemic stroke), but also the safety (more
intracranial bleeding).[4] Indeed, this might partly explain the prevailing perception of warfa-
rin as an ineffective-and-yet-dangerous drug amongst Chinese clinicians, leading to gross
underutilization of the therapy in Chinese and resulting is major missed opportunities for
stroke prevention.
The SAMe-TT2R2 score, which was initially derived and validated in the white Caucasian
population, facilitates decision making by clinicians to help predict the likelihood of achieving
good quality anticoagulation control following the initiation of warfarin therapy.[11] In gen-
eral, patients are expected to have good TTR when the SAMe-TT2R2 score is 0–2, and are at
risk of suboptimal anticoagulation control when the SAMe-TT2R2 score>2. Rather than
imposing a ‘trial of warfarin’ to see if high TTRs can be achieved, and putting such inception
cohort patients at risk of suboptimal INRs and increased stroke risk (by 70%)[17], those
patients with SAMe-TT2R2 score>2 could be targeted upfront for better follow up and educa-
tional efforts [18], or alternative anticoagulant strategies (e.g. non-vitamin K antagonist oral
anticoagulants (NOACs)). Given the overall poor TTR in the Chinese AF population, NOACs
should perhaps be considered as the first line antithrombotic agents for stroke prevention in
non-valvular AF; warfarin therapy might be considered only when NOAC is contraindicated
as in patients with end-stage renal disease.
Similar to the original derivation cohort, [11] an increase in the SAMe-TT2R2 score likewise
resulted in a decrease in TTR in our cohort of Chinese AF patients and as many other non-
Asian cohorts have shown, higher stroke rates [6, 19]. For the same SAMe-TT2R2 score, Chi-
nese AF patients still appear to have a poorer TTR compared with white Caucasians [20],
implying that other strategies (e.g. NOACs) may be better options. As rightly predicted by the
score, around 90% of patients in the present cohort with the SAMe-TT2R2 score2 did not
have good anticoagulation control. This is consistent with epidemiological and trial data show-
ing that Asians seem to do poorly on warfarin with higher risks of thromboembolism and
bleeding (particularly intracranial haemorrahge)[10]. Albeit qualitatively consistent, deviating
the default cutoff value of 2 from the original derivation cohort would still make the score less
useful in Chinese AF population, with a lowered sensitivity and negative predictive value by
such recalibration.
Although the inclusion of an ethnicity component into the SAMe-TT2R2 score appears to a
practical way to improve the predictive power of the score, this may oversimplify the observed
difference in TTR down to ethnicity per se. The reasons underlying poor TTR may be highly
population-specific, ranging from genetic, dietary, behavioural to even health care provision
system. Individual factors constituting the SAMe-TT2R2 score may affect the TTR in different
ways in different ethnic groups with different life-style, value and belief. Most obviously, in the
primarily Caucasian population, younger age represents a risk factor for poor TTR whereas in
SAMe-TT2R2 for Chinese
PLOS ONE | DOI:10.1371/journal.pone.0150674 March 24, 2016 7 / 9
Hong Kong Chinese, younger age may in fact be associated with better understanding to diet
restriction and importance of TTR, which may then in turn translate into a better TTR. Like-
wise in primarily Caucasian population, previous stroke was somehow associated with poor
TTR, but amongst Chinese in Hong Kong, patients with previously stroke had a better TTR,
which may reflect a more compliant lifestyle after stroke. Unfortunately, we lack a parallel Cau-
casian cohort in Hong Kong for comparison. For the SAMe-TT2R2 score, being Chinese is
undoubtedly associated with poor TTR but higher SAMe-TT2R2 score may be the result of a
combination of certain protective factors and risk factors for poor TTR, thus may contribute to
either better or poorer TTR. Additional cultural-specific factors such as the frequency of tradi-
tional Chinese medicine use may be necessary to further improve the performance of the
SAMe-TT2R2 score, but this could be remedied by extending the T criterion of the SAMe-
TT2R2 score for ‘Treatment [interacting drugs]’ to include ‘Treatment [interacting drugs] or
high intake of diet/foods that interfere with warfarin’. Some of the clinical factors within the
SAMe-TT2R2 score are also risk factors for stroke, but the SAMe-TT2R2 score remains a simple
validated score that has been shown to predict labile INRs, thromboembolism, death and seri-
ous bleeding events [19].
Limitations
This study is limited by its registry-based and single-centre observational design in primarily
hospital-based patients. The variance in the management including the overall quality and
facilities offered to patients for anticoagulation control might differ over the study period of 14
years. Information about the frequency and magnitude of warfarin dose changes during follow
up was not recorded in this cohort. We were also suboptimally powered for serious bleeding
events, including intracranial haemorrhage. The choice of target TTR of 70% instead of 65% as
suggested by the NICE guideline in the UK is somewhat arbitrary. However, even the target
TTR is to be lowered to 65%, the percentage of patients achieving the target TTR remains very
small (14.8%).
Conclusion
The SAMe-TT2R2 score correlates well with TTR in Chinese AF patients, with a score>2 hav-
ing high sensitivity and negative predictive values for poor TTR. The risk of ischemic stroke
increased progressively with increasing SAMe-TT2R2 score, consistent with poorer TTRs at
high SAMe-TT2R2 scores.
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